Hyperkalemia associated with intravenous labetalol therapy for acute hypertension in renal transplant recipients.
Three renal transplant recipients developed potentially life-threatening hyperkalemia after receiving intravenous labetalol for postoperative hypertension. Even as beta-adrenergic agonists find increasing use in the therapy of acute hyperkalemia, physicians should be aware of the potential of beta blockers to cause profound elevations of serum potassium.
Arthur
S
S
Department of Medicine, University of Pittsburgh School of Medicine, PA 15261.
Greenberg
A
A
D000328:Adult; D006801:Humans; D006947:Hyperkalemia / Q000139:chemically induced*; D006973:Hypertension / Q000188:drug therapy*; D007262:Infusions, Intravenous; D007676:Kidney Failure, Chronic / Q000601:surgery; D016030:Kidney Transplantation; D007741:Labetalol / Q000009:adverse effects* / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D011183:Postoperative Complications / Q000188:drug therapy*
D007741:Labetalol